KIT
Aliases:
This biomarker is also known as:- Piebald trait
- CD117 antigen
- v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene-like protein
- SCF-sR
- KIT
- CD117
- p145 c-kit
- tyrosine-protein kinase Kit
- soluble KIT variant 1
- mast/stem cell growth factor receptor Kit
- SCFR
- PBT
- proto-oncogene c-Kit
- Piebald trait protein
- C-Kit
- proto-oncogene tyrosine-protein kinase Kit
- v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
Description…
SCF-sR, also known as KIT, is the human homolog of the proto-oncogene c-kit. C-kit was first identified as the cellular homolog of the feline sarcoma viral oncogene v-kit. Human KIT is a tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. KIT is a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). Mutations in this gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous lukemia, and piebaldism. Multiple transcript variants encoding different isoforms have been found for this gene.
Datasets
There are no datasets associated with this biomarker.
Attributes
| QA State: | Curated |
|---|---|
| Type: | Protein |
| HGNC Name: | KIT |
The following organs have data associated with this biomarker…
Attributes
| Phase: | 2 |
|---|---|
| QA State: | Under Review |
Attributes
| Phase: | 2 |
|---|---|
| QA State: | Curated |
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access to this biomarker.
- Multianalyte tests for the early detection of cancer: speedbumps and barriers.
- Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry.
- Coordinate elevation of serum markers in ovarian cancer but not in benign disease.
- Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.
- Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
- TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.
- ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression.